Liquidia Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Liquidia Corporation Common Stock trades at $34.9 (market cap $2.40B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 4.4× Liquidia Corporation Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| LQDA | PCVX | |
|---|---|---|
Market Cap | $2.40B | $10.51B |
Volume | 2,857,547 | 2,644,694 |
Sector | Health | Health |
52-Week High | $91.03 | $73.82 |
52-Week Low | $22.02 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.30B | $9.14B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →